PT2376107E - Oligonucleotídeos imunoestimulantes - Google Patents

Oligonucleotídeos imunoestimulantes Download PDF

Info

Publication number: PT2376107E
Authority: PT; Portugal
Prior art keywords: immunostimulatory oligonucleotides; immunostimulatory; oligonucleotides
Prior art date: 2008-12-09

Application number

PT97749782T

Other languages

English (en)

Inventor

Heather Lynn Davis

Risini Dhammika Weeratna

Original Assignee

Coley Pharm Group Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-09

Filing date

2009-12-01

Publication date

2014-07-25

2009-12-01 Application filed by Coley Pharm Group Inc filed Critical Coley Pharm Group Inc

2014-07-25 Publication of PT2376107E publication Critical patent/PT2376107E/pt

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
230000003308 immunostimulating effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Oncology (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Developmental Biology & Embryology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Toxicology (AREA)

PT97749782T 2008-12-09 2009-12-01 Oligonucleotídeos imunoestimulantes PT2376107E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12102208P	2008-12-09	2008-12-09
US18179909P	2009-05-28	2009-05-28

Publications (1)

Publication Number	Publication Date
PT2376107E true PT2376107E (pt)	2014-07-25

Family

ID=41716468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT97749782T PT2376107E (pt)	2008-12-09	2009-12-01	Oligonucleotídeos imunoestimulantes

Country Status (27)

Country	Link
US (1)	US9453059B2 (pt)
EP (2)	EP2376107B1 (pt)
JP (1)	JP5016733B2 (pt)
KR (1)	KR101329374B1 (pt)
CN (1)	CN102333538B (pt)
AR (1)	AR074501A1 (pt)
AU (1)	AU2009325926B2 (pt)
BR (1)	BRPI0923341B8 (pt)
CA (1)	CA2745096C (pt)
CO (1)	CO6382137A2 (pt)
DK (2)	DK2376107T3 (pt)
ES (2)	ES2481040T3 (pt)
HK (1)	HK1165325A1 (pt)
HU (1)	HUE027823T2 (pt)
IL (1)	IL213162A (pt)
MX (1)	MX2011006088A (pt)
MY (2)	MY160201A (pt)
NZ (1)	NZ593220A (pt)
PE (1)	PE20110998A1 (pt)
PL (2)	PL2376107T3 (pt)
PT (1)	PT2376107E (pt)
RU (2)	RU2477753C2 (pt)
SG (1)	SG171829A1 (pt)
SI (2)	SI2759306T1 (pt)
TW (1)	TWI370740B (pt)
WO (1)	WO2010067262A1 (pt)
ZA (1)	ZA201104048B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2376107E (pt) *	2008-12-09	2014-07-25	Coley Pharm Group Inc	Oligonucleotídeos imunoestimulantes
DK2699587T3 (da)	2011-04-22	2019-08-05	Wyeth Llc	Sammensætninger med relation til et mutant-clostridium difficile-toksin og fremgangsmåder dertil
CA2876150A1 (en)	2012-06-08	2013-12-12	The Johns Hopkins University	Compostions and methods for cancer immunotherapy
BR122016023101B1 (pt)	2012-10-21	2022-03-22	Pfizer Inc	Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN108542913A (zh) *	2012-12-13	2018-09-18	艾杜罗生物科技公司	包含具有确定立体化学的环嘌呤二核苷酸的组合物及其制备和使用方法
SG11201507462QA (en) *	2013-03-14	2015-10-29	Takeda Vaccines Inc	Compositions and methods for live, attenuated alphavirus formulations
SG11201508165VA (en)	2013-04-29	2015-11-27	Sloan Kettering Inst Cancer	Compositions and methods for altering second messenger signaling
EP2992000B1 (en)	2013-05-03	2020-07-08	The Regents of The University of California	Cyclic di-nucleotide induction of type i interferon
US9549944B2 (en)	2013-05-18	2017-01-24	Aduro Biotech, Inc.	Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
BR112015028341A2 (pt)	2013-05-18	2017-07-25	Aduro Biotech Inc	composições e métedos para ativação de "sinalização dependente de estimulador de gene interferon
ES2750608T3 (es)	2013-07-25	2020-03-26	Exicure Inc	Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico
AR097029A1 (es) *	2013-07-26	2016-02-17	Intervet Int Bv	Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
US10176292B2 (en)	2013-07-31	2019-01-08	Memorial Sloan-Kettering Cancer Center	STING crystals and modulators
ES2960793T3 (es) *	2013-09-20	2024-03-06	Nat Inst Biomedical Innovation Health & Nutrition	Complejo que contiene oligonucleótido que tiene actividad inmunoestimulante y su uso
CN103773769B (zh) *	2013-11-08	2016-09-28	上海交通大学	被修饰的含CpG序列单元的寡聚脱氧核苷酸分子及其用途
PL3164113T3 (pl)	2014-06-04	2019-09-30	Exicure, Inc.	Wielowartościowe dostarczanie modulatorów immunologicznych w liposomowych kolistych kwasach nukleinowych do zastosowań profilaktycznych lub terapeutycznych
AU2015349680A1 (en)	2014-11-21	2017-06-08	Northwestern University	The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3357507A4 (en) *	2015-09-30	2019-05-29	Shionogi & Co., Ltd	NUCLEIC ACID DERIVATIVE WITH IMMUNOSTIMULATING EFFECT
BR112018075033A2 (pt) *	2016-06-02	2019-03-26	Zoetis Services Llc	vacina contra bronquite infecciosa
EP3463386A4 (en) *	2016-06-03	2020-03-04	Wave Life Sciences Ltd.	OLIGONUCLEOTIDES, COMPOSITIONS AND METHOD THEREFOR
US11364304B2 (en)	2016-08-25	2022-06-21	Northwestern University	Crosslinked micellar spherical nucleic acids
KR101875055B1 (ko) *	2016-10-19	2018-07-06	연세대학교 원주산학협력단	융합 단백질 및 그의 용도
KR102007203B1 (ko) *	2016-10-20	2019-08-05	연세대학교 원주산학협력단	융합 단백질 및 그의 용도
WO2018209270A1 (en)	2017-05-11	2018-11-15	Northwestern University	Adoptive cell therapy using spherical nucleic acids (snas)
CU24699B1 (es)	2017-08-10	2024-03-05	Yisheng Biopharma Singapore Pte Ltd	Composiciones para tratar y/o prevenir la infección por el virus de la hepatitis b
AU2018343217B2 (en)	2017-09-28	2024-11-07	Pfizer Inc.	Compositions and methods for eliciting an immune response against Clostridium difficile
EP3946444A1 (en)	2019-04-01	2022-02-09	Pfizer Inc.	Compositions and methods for eliciting an immune response against clostridium difficile
US20230076371A1 (en) *	2019-12-13	2023-03-09	Grand Theravac Life Science (Nanjing) Co., Ltd.	Pharmaceutical composition and use thereof
WO2021255690A2 (en)	2020-06-19	2021-12-23	Pfizer Inc.	Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
CN112877275B (zh) *	2021-02-04	2023-03-31	中国农业科学院兰州兽医研究所	Hdac2基因敲除的bhk-21细胞系及其构建方法和应用
CN115252772A (zh) *	2021-04-30	2022-11-01	华普生物技术(江苏)股份有限公司	人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用
TWI802177B (zh) *	2021-12-27	2023-05-11	景岳生物科技股份有限公司	副乾酪乳桿菌gmnl-32之核苷酸用於製備調節免疫能力之醫藥組合物的用途
US20240189410A1 (en)	2022-12-13	2024-06-13	Pfizer Inc.	Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
WO2024226031A1 (en) *	2023-04-22	2024-10-31	Malarvx Inc.	Compositions, devices, systems and methods relating to vaccination and sterile protection against malaria

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4469863A (en)	1980-11-12	1984-09-04	Ts O Paul O P	Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en)	1981-10-23	1991-06-11	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and method of making same
AU568067B2 (en)	1981-10-23	1987-12-17	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and methods of making same
DE4321946A1 (de)	1993-07-01	1995-01-12	Hoechst Ag	Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US5658738A (en)	1994-05-31	1997-08-19	Becton Dickinson And Company	Bi-directional oligonucleotides that bind thrombin
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
EP0772619B2 (en)	1994-07-15	2010-12-08	The University of Iowa Research Foundation	Immunomodulatory oligonucleotides
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en)	1997-05-20	2007-08-22	Ottawa Health Research Institute	Processes for preparing nucleic acid constructs
US6124806A (en)	1997-09-12	2000-09-26	Williams Wireless, Inc.	Wide area remote telemetry
US7393630B2 (en)	1997-12-16	2008-07-01	Novartis Vaccines And Diagnostics, Inc.	Use of microparticles combined with submicron oil-in-water emulsions
WO1999051259A2 (en)	1998-04-03	1999-10-14	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP1733735B1 (en) *	1998-05-22	2017-03-22	Ottawa Hospital Research Institute	Methods and products for inducing mucosal immunity
SE9801923D0 (sv) *	1998-05-29	1998-05-29	Independent Pharmaceutical Ab	Nicotine vaccine
US6232082B1 (en)	1998-12-01	2001-05-15	Nabi	Hapten-carrier conjugates for treating and preventing nicotine addiction
EP1176966B1 (en)	1999-04-12	2013-04-03	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Oligodeoxynucleotide and its use to induce an immune response
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
BR0014236A (pt)	1999-09-25	2002-10-15	Univ Iowa Res Found	cidos nucléicos imunoestimuladores
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
DE60131430T2 (de)	2000-01-14	2008-10-16	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
US20030129251A1 (en)	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
ATE382711T1 (de) *	2000-09-01	2008-01-15	Epigenomics Ag	Verfahren zur bestimmung des methylierungsgrades von bestimmten cytosinen in genomischer dna im sequenzkontext 5'-cpg-3'
GB0031079D0 (en) *	2000-12-20	2001-01-31	Smithkline Beecham Plc	Vaccine
ES2421532T3 (es)	2001-06-21	2013-09-03	Dynavax Tech Corp	Compuestos inmunomoduladores quiméricos y métodos de uso de los mismos
US7785610B2 (en)	2001-06-21	2010-08-31	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same—III
AU2002361468A1 (en)	2001-08-14	2003-03-18	The Government Of The United States Of America As Represented By The Secretary Of Health And Human S	Method for rapid generation of mature dendritic cells
DK1450856T3 (da) *	2001-09-14	2010-05-31	Cytos Biotechnology Ag	Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse
WO2003027313A2 (en)	2001-09-24	2003-04-03	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US7514415B2 (en)	2002-08-01	2009-04-07	The United States Of America As Represented By The Department Of Health And Human Services	Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
AU2002366710A1 (en)	2001-12-20	2003-07-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
EP1480672A2 (en) *	2002-03-01	2004-12-01	The Board of Regents of the University of Nebraska	Compositions and compounds for use as a nicotine vaccine employing response selective agonist of an antigen-presenting cell receptor as a molecular adjuvant
US20040053880A1 (en)	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en)	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en)	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
AU2003259827B2 (en)	2002-08-12	2008-09-04	Dynavax Technologies Corporation	Immunomodulatory compositions, methods of making, and methods of use thereof
US8043622B2 (en)	2002-10-08	2011-10-25	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
BR0315810A (pt)	2002-10-29	2005-09-13	Coley Pharmaceutical Group Ltd	Uso de oligonucleotìdeos cpg no tratamento de infecção por vìrus da hepatite c
US7758876B2 (en)	2002-11-01	2010-07-20	The United States Of America As Represented By The Department Of Health And Human Services	Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
US7956043B2 (en)	2002-12-11	2011-06-07	Coley Pharmaceutical Group, Inc.	5′ CpG nucleic acids and methods of use
EP1578419A4 (en)	2002-12-30	2008-11-12	3M Innovative Properties Co	IMMUNOSTIMULATING COMBINATIONS
CA2521050A1 (en)	2003-04-02	2004-10-14	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
AU2004271972B2 (en)	2003-09-05	2010-06-03	Anadys Pharmaceuticals, Inc.	TLR7 ligands for the treatment of hepatitis C
GB0321615D0 (en)	2003-09-15	2003-10-15	Glaxo Group Ltd	Improvements in vaccination
US7615539B2 (en)	2003-09-25	2009-11-10	Coley Pharmaceutical Group, Inc.	Nucleic acid-lipophilic conjugates
WO2005042018A2 (en) *	2003-10-30	2005-05-12	Coley Pharmaceutical Gmbh	C-class oligonucleotide analogs with enhanced immunostimulatory potency
EP1699814A4 (en) *	2003-12-08	2009-01-14	Hybridon Inc	MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF COMPOUNDS FORMED FROM SMALL OLIGONUCLEOTIDES
EP1776105A2 (en)	2004-07-18	2007-04-25	Coley Pharmaceutical Group, Ltd	Methods and compositions for inducing innate immune responses
MY159370A (en)	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
US20060111271A1 (en) *	2004-11-24	2006-05-25	Cerny Erich H	Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements
EP2351576A1 (en)	2004-12-29	2011-08-03	Mannkind Corporation	Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
EP1874325A2 (en) *	2005-04-08	2008-01-09	Coley Pharmaceutical Group, Inc.	Methods for treating infectious disease exacerbated asthma
CA2620582C (en)	2005-08-31	2015-11-10	Dennis M. Klinman	Methods of altering an immune response induced by cpg oligodeoxynucleotides
EP1963308A4 (en)	2005-11-28	2010-12-15	Nabi Biopharmaceuticals	PROCESS FOR MARKING A NICOTINE HAPTEN
CN104357469B (zh)	2006-05-03	2018-10-26	科罗拉多州立大学董事会	Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其用途
US8273361B2 (en)	2006-09-26	2012-09-25	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
EP2089411A4 (en)	2006-12-04	2010-01-27	Univ Illinois	COMPOSITIONS AND METHODS FOR CANCER TREATMENT WITH CUPREDOXINES AND CPG-RICH DNA
EP2217269B1 (en) *	2007-10-12	2017-04-12	Massachusetts Institute of Technology	Vaccine nanotechnology
US8546337B2 (en) *	2008-02-01	2013-10-01	Alpha-O-Peptides Ag	Self-assembling peptide nanoparticles useful as vaccines
EP2300053A1 (en) *	2008-06-04	2011-03-30	Cornell University	Vaccines for prevention and treatment of addiction
US8728465B2 (en)	2008-06-17	2014-05-20	Cedars-Sinai Medical Center	Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
MX349720B (es) *	2008-06-27	2017-08-09	Zoetis Services Llc	Composiciones adyuvantes novedosas.
US8343498B2 (en) *	2008-10-12	2013-01-01	Massachusetts Institute Of Technology	Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) *	2008-10-12	2013-11-26	The Brigham And Women's Hospital, Inc.	Nicotine immunonanotherapeutics
US8053422B2 (en)	2008-12-04	2011-11-08	The United States Of America As Represented By The Department Of Health And Human Services	Anti-cancer oligodeoxynucleotides
PT2376107E (pt) *	2008-12-09	2014-07-25	Coley Pharm Group Inc	Oligonucleotídeos imunoestimulantes
JP5209800B2 (ja)	2008-12-09	2013-06-12	ファイザーバクシーンズエルエルシー	ＩｇＥＣＨ３ペプチドワクチン
US8552165B2 (en) *	2008-12-09	2013-10-08	Heather Davis	Immunostimulatory oligonucleotides
ES2552153T3 (es) *	2009-04-30	2015-11-26	Coley Pharmaceutical Group, Inc.	Vacuna neumocócica y usos de la misma
EA201500447A1 (ru) *	2009-05-27	2017-03-31	Селекта Байосайенсиз, Инк.	НАЦЕЛЕННЫЕ СИНТЕТИЧЕСКИЕ НАНОНОСИТЕЛИ С pH-ЧУВСТВИТЕЛЬНЫМ ВЫСВОБОЖДЕНИЕМ ИММУНОМОДУЛИРУЮЩИХ СРЕДСТВ
CA2768346A1 (en)	2009-07-30	2011-02-03	Pfizer Vaccines Llc	Antigenic tau peptides and uses thereof
WO2011014679A1 (en) *	2009-07-31	2011-02-03	Nabi Biopharmaceuticals	Method and kit for treating nicotine addiction
MX2012002639A (es)	2009-09-03	2012-03-14	Pfizer Vaccines Llc	Vacuna de pcsk9.
JP2011092108A (ja)	2009-10-30	2011-05-12	Rikkyo Gakuin	シアニジウム類由来のプロトンａｔｐアーゼ遺伝子を用いた耐性植物体の作出方法及び該遺伝子の用途
CN107029222A (zh) *	2010-05-26	2017-08-11	西莱克塔生物科技公司	合成纳米载体联合疫苗
WO2011148356A1 (en) *	2010-05-28	2011-12-01	Coley Pharmaceutical Group, Inc.	Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules
TWI578997B (zh) *	2010-06-04	2017-04-21	輝瑞疫苗有限責任公司	用於預防或治療菸鹼成癮之共軛體
EP2575868A1 (en) *	2010-06-07	2013-04-10	Pfizer Vaccines LLC	Ige ch3 peptide vaccine
DK2699587T3 (da) *	2011-04-22	2019-08-05	Wyeth Llc	Sammensætninger med relation til et mutant-clostridium difficile-toksin og fremgangsmåder dertil
RU2636350C2 (ru) *	2011-11-07	2017-11-22	Новартис Аг	МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
US20150017201A1 (en) *	2013-03-15	2015-01-15	Regents Of The University Of Minnesota	Novel nicotine dna vaccines

2009
- 2009-12-01 PT PT97749782T patent/PT2376107E/pt unknown
- 2009-12-01 ES ES09774978.2T patent/ES2481040T3/es active Active
- 2009-12-01 EP EP09774978.2A patent/EP2376107B1/en active Active
- 2009-12-01 AU AU2009325926A patent/AU2009325926B2/en not_active Ceased
- 2009-12-01 HU HUE14161886A patent/HUE027823T2/hu unknown
- 2009-12-01 PE PE2011001201A patent/PE20110998A1/es active IP Right Grant
- 2009-12-01 EP EP14161886.8A patent/EP2759306B1/en active Active
- 2009-12-01 MY MYPI2011002378A patent/MY160201A/en unknown
- 2009-12-01 SI SI200931411A patent/SI2759306T1/sl unknown
- 2009-12-01 BR BRPI0923341A patent/BRPI0923341B8/pt not_active IP Right Cessation
- 2009-12-01 JP JP2011540283A patent/JP5016733B2/ja active Active
- 2009-12-01 PL PL09774978T patent/PL2376107T3/pl unknown
- 2009-12-01 DK DK09774978.2T patent/DK2376107T3/da active
- 2009-12-01 CA CA2745096A patent/CA2745096C/en active Active
- 2009-12-01 SG SG2011038270A patent/SG171829A1/en unknown
- 2009-12-01 MY MYPI2015000983A patent/MY172421A/en unknown
- 2009-12-01 SI SI200930939T patent/SI2376107T1/sl unknown
- 2009-12-01 DK DK14161886.8T patent/DK2759306T3/en active
- 2009-12-01 RU RU2011122418/10A patent/RU2477753C2/ru active
- 2009-12-01 MX MX2011006088A patent/MX2011006088A/es active IP Right Grant
- 2009-12-01 WO PCT/IB2009/055444 patent/WO2010067262A1/en active Application Filing
- 2009-12-01 CN CN200980149607.3A patent/CN102333538B/zh not_active Expired - Fee Related
- 2009-12-01 NZ NZ593220A patent/NZ593220A/xx not_active IP Right Cessation
- 2009-12-01 ES ES14161886.8T patent/ES2572563T3/es active Active
- 2009-12-01 KR KR1020117015657A patent/KR101329374B1/ko active IP Right Grant
- 2009-12-01 PL PL14161886.8T patent/PL2759306T3/pl unknown
- 2009-12-07 AR ARP090104733A patent/AR074501A1/es active IP Right Grant
- 2009-12-08 TW TW098141948A patent/TWI370740B/zh not_active IP Right Cessation
2011
- 2011-05-26 IL IL213162A patent/IL213162A/en active IP Right Grant
- 2011-05-31 ZA ZA2011/04048A patent/ZA201104048B/en unknown
- 2011-06-10 CO CO11072590A patent/CO6382137A2/es active IP Right Grant
2012
- 2012-06-27 HK HK12106265.1A patent/HK1165325A1/xx not_active IP Right Cessation
- 2012-11-27 RU RU2012150453A patent/RU2610690C2/ru active
2013
- 2013-06-28 US US13/930,213 patent/US9453059B2/en active Active

Also Published As

Publication number	Publication date
KR20110102424A (ko)	2011-09-16
CA2745096A1 (en)	2010-06-17
PL2376107T3 (pl)	2014-09-30
DK2759306T3 (en)	2016-05-09
IL213162A0 (en)	2011-07-31
CA2745096C (en)	2013-11-05
ES2572563T3 (es)	2016-06-01
HUE027823T2 (hu)	2016-11-28
MY172421A (en)	2019-11-25
AU2009325926A1 (en)	2011-06-30
US20150086610A1 (en)	2015-03-26
SI2759306T1 (sl)	2016-05-31
KR101329374B1 (ko)	2013-11-14
ZA201104048B (en)	2012-02-29
PL2759306T3 (pl)	2016-09-30
CN102333538A (zh)	2012-01-25
AU2009325926B2 (en)	2013-05-16
NZ593220A (en)	2012-10-26
EP2376107B1 (en)	2014-05-21
EP2759306B1 (en)	2016-04-06
BRPI0923341A2 (pt)	2018-05-29
RU2012150453A (ru)	2014-06-10
SG171829A1 (en)	2011-07-28
MY160201A (en)	2017-02-28
BRPI0923341B8 (pt)	2021-05-25
CN102333538B (zh)	2014-01-15
RU2477753C2 (ru)	2013-03-20
ES2481040T3 (es)	2014-07-29
US9453059B2 (en)	2016-09-27
TWI370740B (en)	2012-08-21
RU2011122418A (ru)	2013-01-20
AR074501A1 (es)	2011-01-19
EP2759306A1 (en)	2014-07-30
JP5016733B2 (ja)	2012-09-05
HK1165325A1 (en)	2012-10-05
JP2012511321A (ja)	2012-05-24
EP2376107A1 (en)	2011-10-19
TW201026323A (en)	2010-07-16
RU2610690C2 (ru)	2017-02-14
BRPI0923341B1 (pt)	2021-04-06
SI2376107T1 (sl)	2014-07-31
WO2010067262A1 (en)	2010-06-17
IL213162A (en)	2016-08-31
PE20110998A1 (es)	2012-02-10
CO6382137A2 (es)	2012-02-15
DK2376107T3 (da)	2014-07-07
MX2011006088A (es)	2011-06-21

Publication	Publication Date	Title
TWI370740B (en)	2012-08-21	Immunostimulatory oligonucleotides
IL252061A0 (en)	2017-07-31	Oligonucleotides that stimulate the immune system
GB0821457D0 (en)	2008-12-31	Oligonucleotides
EP2280616A4 (en)	2012-11-21	BODY FOR BABY
EP2257170A4 (en)	2011-08-03	TÉTRAHYDROFUROPYRIDONES
GB0800702D0 (en)	2008-02-20	Genes
EP2285758A4 (en)	2013-01-02	DISPOSABLE PACKAGING FOR FERTILIZER-PESTICIDE
EP2313147A4 (en)	2013-05-22	crimping
EP2285375A4 (en)	2011-06-15	SPIROAZAINDOLE
GB0800389D0 (en)	2008-02-20	Gileo hang-it
GB0800161D0 (en)	2008-02-13	Rota-board
GB0920389D0 (en)	2010-01-06	Novel oligonucleotides
AU3972P (en)	2010-03-02	Tobruk xTriticosecale
AU3935P (en)	2009-12-24	DPV308 Dianella prunina
AU3977P (en)	2010-03-09	PARV01 Myoporum parvifolium
AU4098P (en)	2010-09-29	NPW2 Dianella tasmanica
IL191964A0 (en)	2009-02-11	Al teker
GB0803872D0 (en)	2008-04-09	Microarrays
GB0821899D0 (en)	2009-01-07	Easybrush it
GB0812697D0 (en)	2008-08-20	Enzyme-pore constructs
GB0800531D0 (en)	2008-02-20	Webcanvas
AU2008294V (en)	2009-02-03	Bogong xTriticosecale
GB0800299D0 (en)	2008-02-20	Multi-cleaner
AU2008295V (en)	2009-02-09	Canobolas xTriticosecale
GB0800296D0 (en)	2008-02-20	Teletruck